Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Maintenance After Chemoradiotherapy for Lung Adenocarcinoma
NCT03904563Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in lung adenocarcinoma, sponsored by Sun Yat-sen University. Primary endpoints: Progression-free survival at 3 years and Rate of grade >=2 radiation pneumonia at 1 year. Started Jan 2019; status: completed.
02
Drugs
bevacizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03904563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904563.